Followers | 88 |
Posts | 8196 |
Boards Moderated | 0 |
Alias Born | 06/17/2013 |
![](https://investorshub.advfn.com/uicon/404071.png?cb=1506674193)
Tuesday, September 07, 2021 9:03:10 AM
Phase III Cell Therapy Company to Leverage Clinical and Immunological Experience of Korean Clinical Developments to Develop Cancer Killing Therapies
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-signs-memorandum-of-understanding-with-clinical-stage-immunotherapy-company-eutilogics-inc-to-explore-augmentation-of-synergies-between-stemvacs-v-and-tast-301370149.html
ELK CITY, Idaho, Sept. 7, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies.
Eutilex has developed an autologous immunotherapy for tumors which unleash the endogenous ability of T cells to selectively kill tumor cells, even in solid tumors, which will be commercially developed in the US by Eutilogics. As the discoverer of CD137 (4-1BB) and AITR receptors, Eutilogics CEO, Dr. Byoung S. Kwon, is an internationally renowned expert of the immune system, and TAST is a globally competitive targeted cell therapy treatment, which is the result of the validation of decades of research and development.
Therapeutic Solutions International has recently filed an Investigational New Drug application for its StemVacs-V tumor-angiogenesis targeting immunotherapy in breast cancer. StemVacs-V has been demonstrated to induce immune responses to kill blood vessels that feed tumors. StemVacs-V has demonstrated superior tumor inhibition in comparison to other blood vessel targeting immunotherapies in animal models.
"Having collaborated with scientists from Therapeutic Solutions International for several years, we are eager to take our work to the next level through this memorandum of understanding formalizing our collaboration," said Dr. Byoung S. Kwon. "Given that Therapeutic Solutions International has synergistic expertise in cell therapy, we hope to advance more treatment options for patients, much faster."
"Eutilex has been a pioneer in creating novel immunotherapies that leverage the unique molecule 4.1 BB, which is one of the keys in creating an optimized T cell response against tumors. We hope to leverage this technology to kill tumor blood vessels, which appear to be more sensitive towards immunologically based targeting," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
ir@tsoimail.com
SOURCE Therapeutic Solutions International
Related Links
therapeuticsolutionsint.com
Recent TSOI News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:51:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 04:47:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:46:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:44:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/30/2024 06:46:26 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 04:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:17:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 05:44:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:24:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 11:10:01 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM